Clinical Study to Assess the Efficacy of Once-daily IMM-124E (Travelan®) in a Controlled Human Infection Model.
Trial details
- Registry ID
- NCT05933525
- Drugs studied
- Travelan
TrialRedline tracks 1 clinical trial sponsored by Immuron Ltd.: 1 Phase 2.
Company identity checked against sources
| Trial | Drugs studied | Status | Primary completion |
|---|---|---|---|
| Clinical Study to Assess the Efficacy of Once-daily IMM-124E (Travelan®) in a Controlled Human Infection Model.NCT05933525 | Travelan | Completed | 2024-07-01Actual |
Names as written in the registry records.
Text changed; whether the study measures changed has not been verified. Saved text may be shortened.
Before: Measure: To Measure the Protective Efficacy of Oral Administration of Travelan Compared to Placebo Against Moderate-to-severe Diarrhea Following With E.Coli (ETEC) Challenge.. After: Measure: Protective Efficacy of a Single Daily Dose of Travelan Against Moderate-to-severe Diarrhea Following Challenge With Enterotoxigenic E. Coli (ETEC) Strain H10407..
Text changed; whether the study measures changed has not been verified. Saved text may be shortened.
Before: Measure: To measure the protective efficacy of oral administration of Travelan compared to placebo against moderate-to-severe diarrhea following with E.coli (ETEC) challenge.. After: Measure: To Measure the Protective Efficacy of Oral Administration of Travelan Compared to Placebo Against Moderate-to-severe Diarrhea Following With E.Coli (ETEC) Challenge..
Before: 60 participants (actual). After: 63 participants (actual).